dexmedetomidine has been researched along with Disease Exacerbation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haghdoost-Yazdi, H; Minaei, A | 1 |
| Chen, P; Dai, G; Hong, J; Jiang, Y; Li, A; Lin, W; Luo, X; Luo, Y; Ning, X; Peng, S; Qu, C; Wang, H; Xie, P | 1 |
| Bai, Y; He, H; Huang, L; Liu, W; Zhang, P | 1 |
| Araki, Y; Kondo, G; Kurimoto, M; Muraoka, S; Okamoto, S; Ota, S; Shiba, Y; Uda, K; Wakabayashi, T | 1 |
| Liu, T; Wang, X; Yao, Y; Zhang, D | 1 |
| Cajochen, C; Dalmau, J; Embid, C; Gaig, C; Graus, F; Iranzo, A; Santamaria, J; Vilaseca, I | 1 |
| Brown, EB; Burke, KA; Dawes, RP; Madden, KS; Szpunar, MJ | 1 |
| Bruzzone, A; Copsel, S; Davio, C; Galés, C; Gargiulo, L; Lüthy, IA; Rivero, EM; Sénard, JM | 1 |
| Chen, Y; Deng, F; Ouyang, M; Sun, X; Tang, J; Tao, T; Wang, X; Xu, L; Yao, X; Zhao, L | 1 |
| Altunbaş, K; Aslan, A; Baş, O; Buyukokuroglu, ME; Cemek, M; Cosar, M; Ela, Y; Eser, O; Fidan, H | 1 |
10 other study(ies) available for dexmedetomidine and Disease Exacerbation
| Article | Year |
|---|---|
Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced parkinsonism; involvement of K
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Progression; Inflammation Mediators; KATP Channels; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2 | 2019 |
Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemokines; Dexmedetomidine; Disease Models, Animal; Disease Progression; Hepatic Stellate Cells; Humans; Interleukin-6; Liver Cirrhosis; Liver Neoplasms; Male; Mice, Inbred C57BL; Neoplasm Metastasis; Receptors, Adrenergic, alpha-2; STAT3 Transcription Factor | 2020 |
Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis.
Topics: Adaptor Proteins, Signal Transducing; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Dexmedetomidine; Disease Progression; Down-Regulation; Esophageal Neoplasms; Humans; Mice; MicroRNAs; Neoplasm Metastasis; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Postoperative Cerebral Infarction Risk Factors and Postoperative Management of Pediatric Patients with Moyamoya Disease.
Topics: Adolescent; Analgesics; Barbiturates; Cerebral Infarction; Cerebral Revascularization; Child; Child, Preschool; Dexmedetomidine; Disease Management; Disease Progression; Female; Fentanyl; Humans; Hypnotics and Sedatives; Incidence; Magnetic Resonance Imaging; Male; Moyamoya Disease; Neuroimaging; Postoperative Complications; Quality of Life; Risk Factors | 2018 |
The Contrary Effects of Sirt1 on MCF7 Cells Depend on CD36 Expression Level.
Topics: Adrenergic alpha-2 Receptor Agonists; Breast; Breast Neoplasms; CD36 Antigens; Cell Proliferation; Dexmedetomidine; Disease Progression; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Resveratrol; Signal Transduction; Sirtuin 1; Up-Regulation | 2019 |
Characterization of the sleep disorder of anti-IgLON5 disease.
Topics: Actigraphy; Aged; Autoimmune Diseases; Cell Adhesion Molecules, Neuronal; Dexmedetomidine; Disease Progression; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Movement; Parasomnias; Polysomnography; REM Sleep Behavior Disorder; Sleep Apnea, Obstructive; Sleep, Slow-Wave | 2019 |
The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure.
Topics: Adenocarcinoma; Adrenergic alpha-2 Receptor Agonists; Animals; Antidepressive Agents, Tricyclic; Apoptosis; Breast Neoplasms; Cell Proliferation; Collagen; Cytokines; Desipramine; Dexmedetomidine; Disease Progression; Female; Humans; Image Processing, Computer-Assisted; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence, Multiphoton; Norepinephrine; Receptors, Adrenergic, alpha-2; Tumor Cells, Cultured | 2013 |
Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines.
Topics: Adrenergic beta-2 Receptor Agonists; Breast Neoplasms; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Proliferation; Dexmedetomidine; Disease Progression; Epinephrine; Female; Gene Knockdown Techniques; Humans; Isoproterenol; MCF-7 Cells; Phenotype; Receptors, Adrenergic, beta-2; Signal Transduction; Transfection | 2014 |
Differential role of intravenous anesthetics in colorectal cancer progression: implications for clinical application.
Topics: Anesthetics, Intravenous; Animals; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Dexmedetomidine; Disease Progression; Epithelial-Mesenchymal Transition; Etomidate; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Prognosis; Propofol; Proto-Oncogene Proteins c-akt; Signal Transduction | 2016 |
Does dexmedetomidine reduce secondary damage after spinal cord injury? An experimental study.
Topics: Adrenergic alpha-Agonists; Animals; Antioxidants; Apoptosis; Dexmedetomidine; Disease Models, Animal; Disease Progression; Energy Metabolism; Female; Lipid Peroxidation; Male; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Paraplegia; Rabbits; Spinal Cord; Spinal Cord Injuries; Treatment Failure | 2009 |